Arena Pharma's Q2 Earnings Soar - Analyst Blog

By
A A A

Arena Pharmaceuticals, Inc. 's ( ARNA ) earnings (excluding special items) of 17 cents per share in the second quarter of 2013 were higher than the breakeven earnings reported a year ago. Second quarter earnings also beat the Zacks Consensus Estimate of 13 cents.

Quarterly Update

Arena Pharma recorded second quarter revenues of $68.9 million, a massive increase of 213% from the year-ago period, thanks to a $65 million milestone payment received from partner Eisai related to Belviq.


In Jun 2013, Arena Pharma launched its obesity drug, Belviq, in the U.S. Second quarter results reflect the first three weeks of Belviq sales after its launch with Arena Pharma recording Belviq sales of $1.3 million. About 12,500 prescriptions for Belviq were written until Jul 19.

The company's revenues were well above the Zacks Consensus Estimate of $48 million. During the reported quarter, the company received a $0.5 million milestone payment from Eisai for the New Drug Submission in Canada for Belviq.

Research and development (R&D) and general and administrative (G&A) expenses were up 33.3% to $18.8 million and 65.4% to $8.6 million during the reported quarter, respectively.

Arena Pharma expects R&D spend of $70 million to $78 million and G&A spend of $28 million to $34 million in 2013.

Other Developments

Arena Pharma's commitment for expanding the market reach of Belviq was evident in the quarter through strategic collaborations with local established players in countries outside the U.S.

In Jul 2013, Arena Pharma entered into an agreement with Taiwan-based CY Biotech for the marketing and supply agreement of Belviq in Taiwan.

The obesity market represents huge commercial potential. According to the World Health Organization (WHO), the worldwide obese population has almost doubled since 1980. Furthermore, 1.5 billion people around the globe are overweight with 500 million falling under the obese category.

We note that the company is also evaluating Belviq for additional indications and its administration with other agents such as appetite suppressant, phentermine.

We are encouraged by the company's efforts to develop its pipeline along with the expansion of the Belviq label. During the reported quarter, the company progressed on its pipeline candidates, APD811, APD334 and temanogrel, which are being developed for indications other than obesity.

Currently, Arena Pharma carries a Zacks Rank #3 (Hold). Biopharma stocks which look attractive include Actelion Ltd. ( ALIOF ) with a Zacks Rank #1 (Strong Buy), and Medivation, Inc. ( MDVN ) and Jazz Pharmaceuticals Public Limited Company ( JAZZ ) with a Zacks Rank #2 (Buy).



ACTELION LTD (ALIOF): Get Free Report

ARENA PHARMA (ARNA): Free Stock Analysis Report

JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Earnings , Stocks

Referenced Stocks: ALIOF , ARNA , JAZZ , MDVN

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com